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Abstract 
Background. Women on opioid substitution treatment (WOST) are at heightened risk for the 
sexual transmission of sexually transmitted infections and blood-borne viruses. This study 
aimed to explore the opportunities to promote their sexual health in community pharmacies in 
England. Methods. Semi-structured interviews were conducted with 20 WOST and 14 
community pharmacists (CPs). A focus group was run with three CPs. Participants were 
recruited in drug services and a service for sex workers (WOST), and in community pharmacies 
(CP). Data collection took place between October 2016 and September 2017. Data were 
analysed using Framework Analysis and directed Content Analysis. Results. CPs could play a 
role in promoting sexual health among WOST. Sexual health screening, treatment, and condom 
supply were suggested as potential ways of delivering pharmacy-based sexual health services. 
These services should be actively offered to WOST, delivered in a private space and free of 
cost. We identified several challenges to overcome in order to design and implement sexual 
health services for WOST in community pharmacies. Conclusions. This study highlights the 
potentially key role CPs can have promoting sexual health and addressing health inequities 
among WOST. Improvements in pharmacists’ training are required in order to address stigma 
towards WOST, and promote trust and positive rapport. Structural changes are also needed to 
broaden the services available for this group of women and improve their access to healthcare. 
Keywords 
Women; Sexual health; Opioid substitution treatment; Qualitative research; Community 
pharmacy 
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Introduction 
People who use drugs (PWUD) are at high risk of sexually transmitted infections (STIs) and 
blood-borne viruses (BBVs) – i.e., HIV, Hepatitis B and C – (1-10). Most preventive strategies 
for PWUD have focused on the prevention of HIV and Hepatitis C, especially among people 
who inject drugs. These have generally overlooked the prevention of STIs and the sexual 
transmission of BBVs (11-14). Women are especially vulnerable to STIs and BBVs. This is due 
to several factors at different social ecological levels (15). Socio-structural factors include 
gender inequities, gender-based violence, and intersectional stigma. At the individual-level, 
feelings of love and trust are among barriers for condom use.   
Amongst drug-using women, women on opioid substitution treatment (WOST) are an accessible 
group as they attend social and health services on a regular basis, most notably their community 
pharmacy where they collect their opioid substitution treatment (OST). In the United Kingdom 
(UK), WOST often collect OST from community pharmacies on a daily basis. Community 
pharmacists (CPs) in the UK are highly accessible and key in delivering public health services, 
with an expanding role in health promotion (16-17). Sexual and reproductive health services for 
the general population, including STI screening and provision of emergency hormonal 
contraception, are already available in community pharmacies across the UK. Community 
pharmacy services for WOST are limited to dispensing OST and harm reduction strategies to 
prevent BBVs (e.g., needle exchange programs) (18). There is thus an opportunity to explore 
whether CPs could provide more holistic care to WOST, including sexual health promotion. 
But, research is needed to design and implement sexual health services that meet the needs of 
WOST and reach this vulnerable group. Making sexual health services available for WOST 
alongside their OST presents an opportunity to improve access to healthcare and reduce health 
inequities for this group of women.   
This study explores this opportunity to promote sexual health among WOST in community 
pharmacy, considering the perspectives of this group of women and CPs. It is part of a larger 
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project that aims to design a pharmacy-based sexual health service for WOST. This paper 
addresses three objectives of this project: 1) explore the role of CPs in preventing STIs and 
BBVs among WOST, 2) characterise key components of a service in community pharmacy to 
promote sexual health among WOST, and 3) identify potential challenges.  
Methods 
This qualitative study adopted a pragmatic approach to epistemology and ontology (19-20).  
Pragmatism was considered to be the most appropriate approach for this study as it offered the 
flexibility and freedom to choose the methods and procedures that were most relevant for each 
stage of the study. Research quality was assessed based on the criteria by Yardley (2000, 2015, 
2017). Data from this study has already been published (23).   
Recruitment Strategy   
Recruitment of WOST was opportunistic and venue-based in drug services and a service for sex 
workers in South West England (Bath, Midsomer Norton and Bristol). Previous studies with 
hard-to reach populations have used similar recruitment strategies (19). CPs were recruited 
through community pharmacies in the same localities.  
The researchers sought diversity in participants’ discourses by considering different variables. 
Some of the variables considered for WOST were age, experiences of sex work and 
homelessness, and type and OST treatment progress. Age, sex, employment status and level of 
responsibility at work, and type and location of community pharmacies were considered for 
CPs.   
A total of 75 WOST were approached to participate in the study by the PI (LMP). It is unknown 
the exact number of women who were informed about the study by the services’ staff. Even just 
considering the 75 women directly approached by the PI, nearly ¾ of women declined (73,3%). 
The number of women who refused to take in the study was however considerably higher. The 
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PI contacted 94 community pharmacies. Fourteen CPs agreed to the participate (refusal rate 
85,1%). 
A £10 LovetoShop voucher (multi-retailer gift voucher available in the UK) was offered to all 
participants. 
Data Collection 
Thirty-four semi-structured face-to-face interviews were conducted with WOST (N=20) and 
CPs (N=14) over seven months between October 2016 and April 2017. One focus group with 
CPs (N=3) was also run on September 21st 2017. Data were collected until saturation was 
reached. The duration of the interviews was between 25 and 90 minutes. The focus group lasted 
60 minutes. 
Interview topic guides were developed in collaboration with key informants (e.g., past drug 
services’ users) (see Appendices 1-3). All participants completed a questionnaire on 
demographics, sexual health and drug use (WOST) and on demographics (CPs) (see Tables 1-
3). 
Data Analyses  
All data collection sessions were audio recorded and transcribed verbatim. The interviews were 
analysed using Framework Analysis (20) and the focus group using Directed Qualitative 
Content Analysis (21). Data were primarily analysed by one of the researchers (LMP) with the 
support and guidance of the rest of team. NVivo software version 10 was used for the analysis. 
Descriptive statistics of the questionnaire data were undertaken, using SPSS software. 
Reflexivity was also part of the data analysis process.   
Ethical Considerations  
This study received ethical approval from the [institution granting ethical approval] on the 17th 
of August 2016 [reference numbers ethical approvals]. Informed consent was obtained from all 
participants.  
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Results 
Data from semi-structured interviews and the focus group were merged for both groups of 
participants and are presented below. See Tables 1-3 for participant characteristics. Main 
findings are structured by the paper’s aims and in two sections: the role of community 
pharmacists, and potential challenges. 
The role of community pharmacists and key components for pharmacy services to 
promote sexual health 
All participants considered it acceptable that community pharmacies offered sexual health 
services. Both groups recognized that, in principle, community pharmacy was very well placed 
to provide these services. This was due to frequent contact, pharmacies’ opening hours, 
anonymity, lack of appointments, and (generally) positive rapport between WOST and CPs. 
However, it appeared that sexual health was rarely discussed. The development of a pharmacy-
based sexual health service could then be an opportunity to improve the sexual health and 
access to care for WOST.   
Most CPs believed that, overall, they were well-prepared to deliver sexual health services to 
WOST and that community pharmacy was an appropriate setting for these services. They 
considered that with the appropriate training other pharmacy staff (i.e., technicians, dispensers 
and counter assistants) could be part of providing the service. The role of each professional 
would depend on the components of the service, and the knowledge and skills required to 
deliver it.   
There were several ideas for developing a sexual health service for WOST in community 
pharmacy. Suggestions for the components of the service included short consultations, condom 
supply, sexual health screening and STI/BBV treatment. Working together with other pharmacy 
staff, and liaising with other health and social care professionals would be essential, according 
to most participants. They also mentioned how referrals to appropriate professionals would need 
to be made available when appropriate (e.g., to start anti-retroviral therapy for HIV). This would 
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not only include referrals for health-related issues but also safeguarding concerns (e.g., gender-
based violence). In pharmacies with more resources and capacity, a walk-in sexual health clinic 
could be organized to exclusively deliver this service.  
Potential challenges to overcome  
Based on the participants’ narratives, we identified several challenges for promoting sexual 
health among WOST in community pharmacy. These were: 1) intersectional stigma and 
discrimination; 2) trust and humanity; 3) lack of privacy and time constraints; and 4) financial 
limitations.   
Intersectional stigma and discrimination: beyond drug use  
Intersectional stigma refers to a qualitatively unique experience of stigma that results from the 
overlap of interdependent stigmatized identities (22). In the case of WOST and in relation to a 
recent paper (23), experiences of intersectional stigma were associated with the female gender, 
drug use, transactional sex, homelessness and sexual health status. Women’s narratives also 
highlighted how OST (and especially methadone) was stigmatized because of its association 
with drug use.  
Women’s narratives indicated a relationship between experiencing stigma and a lack of access 
and engagement with healthcare services. They expressed how they had, at some point, felt 
stigmatized and discriminated against in community pharmacies. This was either by CPs, other 
pharmacy staff or other pharmacy clients. Facing situations of stigmatization and discrimination 
left WOST feeling ashamed, helpless and reluctant to access services in community pharmacy.   
It was relatively common that CPs dichotomized clients into “not normal” (WOST) and 
“normal” (any other pharmacy clients). CPs sometimes seemed to be unaware of their own 
stigmatizing attitudes towards OST clients. Other times participants were aware of their own 
attitudes and tried to amend them explicitly (“well I should not say normal”). Some CPs 
referred to OST clients using stigmatizing and dehumanizing terms such as: “these people”, 
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“addicts”, “blue scripts” – OST clients have a blue script rather than green in the UK –, or 
“drunks”. Also, a few CPs viewed PWUD as “a public health and public safety issue” for the 
general population. Working on BBV prevention with OST clients was even perceived as a risk 
for pharmacists to contract HIV. This displays the idea of PWUD as carriers of disease (and 
especially HIV), which is another example of stigmatizing views and attitudes that some 
pharmacists may hold. Some CPs recognized that the stigma towards PWUD was a barrier for 
health promotion and engaging WOST in health services.  
We identified differences in how CPs viewed drug use and OST. Some stigmatizing attitudes 
towards PWUD (and thus OST clients)appeared to be associated with the experiences and 
socially-constructed meanings of drug use of CPs..   
Trust and humanity: building positive rapport and good communication  
Except for one participant, all WOST felt comfortable in their current community pharmacy and 
with the rapport and interactions that they had with their CPs. Some participants explained the 
positive role that their CPs had had in their progression towards recovery from drug use. 
Women felt that some CPs cared for them as they had helped them in the past with their OST 
and other personal matters. Building a relationship of trust was important for WOST to feel 
comfortable in their community pharmacy and to be willing to engage in pharmacy services.   
At the same time, WOST perceived that pharmacists and other professionals had a limited 
understanding and misconceptions about their life experiences and the context of drug use. 
There seemed to be a gap in the realities of WOST and CPs that was difficult to bridge, as 
pharmacists appeared to view drug use as an individual-level phenomena. This maintained and 
strengthened feelings of isolation and helplessness among WOST, and could hinder good 
communication and building trust and positive rapport between WOST and CPs.   
CPs thought most interactions with WOST as being positive, which diverges from WOST’s 
experiences of intersectional stigma. Some emphasized the importance of having a positive 
rapport with WOST and called for a humane treatment of WOST. Working with WOST was 
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however seen as challenging. CPs experienced it as rewarding when WOST progressed in their 
treatment, but as frustrating when they were either not progressing or relapsing back to drug 
use. Involvement of OST clients in thefts or arguments damaged the rapport and hindered good 
communication and understanding between clients and pharmacists. It was explained that these 
incidents could sometimes make CPs resentful and could create an environment of distrust. 
When such incidents were repeated, CPs suspended the OST and transferred clients to another 
community pharmacy. They were perceived to be a barrier to engage WOST in pharmacy 
services, and limited CPs willingness to deliver services to WOST.   
Lack of privacy and time constraints: providing a space and time to share    
Even though all community pharmacies had a private consultation room, time constraints were 
significant barriers for having private consultations. This lack of privacy in pharmacy seemed to 
exacerbate experiences of stigma and discrimination. Women felt ashamed to be identified as a 
PWUD when they were picking up their medication in community pharmacy, especially if by 
someone they knew.  
Time constraints were identified as main barriers to deliver health promotion services in 
community pharmacy. WOST also mentioned that they were less likely to express health-related 
concerns and engage in services with CPs having short time for consultations. According to 
CPs, delivering additional services (e.g., a new sexual health service) within current resources 
would be highly restricted by time and workload pressures.   
Financial limitations: community pharmacy as a business   
CPs explained that public health services were commissioned, usually directly by the NHS or 
through Clinical Commissioning Groups1 or local authorities. Several CPs highlighted that 
community pharmacies are businesses and that the services they provide need to translate into 
 
1 Clinically-led statutory NHS bodies responsible for the planning and commissioning of health care 
services for their local area. 
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financial gains. Some CPs feared losing clients if they had a high volume of OST clients, 
therefore losing pharmacy income.  
Financial constraints were not identified by WOST as they may not have been aware of the 
business and financial side of community pharmacy. 
Discussion 
Community pharmacists have been identified to have a key role in promoting health (16-18). 
Our findings suggest that there are opportunities for CPs to get involved in delivering sexual 
health services for WOST. There were several suggestions for the components of a pharmacy-
based sexual health service: having short consultations, condom supply, sexual health screening, 
and STI/BBV treatment. Proactively advertising and providing these services in private would 
be key to engage WOST. Working with other professionals, including other pharmacy staff, 
would be necessary. Specific training for all pharmacy staff would be fundamental, especially to 
equip pharmacists with the necessary skills to initiate a discussion on sexual health and be able 
to deal with sensitive topics. Drug services’ staff and GPs may need to be involved in engaging 
WOST in the service, and communicate effectively with CPs to provide holistic, quality and 
person-centred care.  
There are important barriers at the social and structural level that need to be considered and 
addressed. These seemed somehow to challenge the positive views towards having pharmacy-
based sexual health services for WOST. Abandoning individual-level approaches and taking a 
social ecological perspective to address these challenges at other levels (i.e., social and 
structural) is then essential (24).   
Even though most interactions between WOST and CPs were deemed to be positive, women 
still felt stigmatized and discriminated by pharmacy staff (including CPs) and other clients. This 
is an important barrier to accessing pharmacy services, especially for vulnerable and 
marginalized populations such as WOST. We suspect that experiences of stigma and 
discrimination may have been under-reported by women. Despite the efforts of providing a safe 
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space for WOST to share their experiences, data collection took place mostly within drug 
services that they attend on a regular basis. There is the possibility that some participants may 
have felt cautious to share their experiences of community pharmacy. Stigmatizing attitudes 
seemed to be embedded within most CPs, and some were unaware of their own attitudes 
towards WOST. As health professionals, most pharmacists were mindful of the need to deliver 
non-judgmental and patient-centred consultations. However, this was not always applied in 
practice. The way some pharmacists talked about WOST showed how ingrained stigma towards 
PWUD is (23, 25-28). The fact that CPs may not even be aware of their own stigmatizing 
attitudes may increase the complexity of stigma reduction strategies for community pharmacy. 
Also, CPs taking part in this study could potentially hold less negative views on OST clients, 
compared to other pharmacists who were not interested in participating. However, we did not 
interview other pharmacy staff (e.g., counter assistants) and these other professionals also 
interact daily with WOST. Future research could explore their views and attitudes towards 
WOST in order to provide a more holistic picture of stigma and discrimination in community 
pharmacy. Strategies to reduce stigma in community pharmacy should be a priority to deliver 
health services to WOST effectively. These could include training programs for pharmacy staff, 
patient-centred approaches for health services (that are applied in practice), new and/or 
improved policies considering and addressing stigma, rights-based policy approaches (29).  
The “blame culture” towards PWUD prevails. Drug use is commonly attributed to individual 
factors (e.g., personality) rather than socio-structural factors (e.g., poverty). It would be 
expected that health professionals working with PWUD (e.g., pharmacists working with 
WOST) would be familiar with the multidimensionality and complexity of drug use. 
Interestingly, this was not what we encountered in our research. A few pharmacists still viewed 
drug use and healthcare from a reductionist and biomedical perspective, which calls for a review 
of pharmacists’ training (30). These misconceptions about the realities of WOST may limit their 
access to healthcare and contribute to maintaining health inequities among this group. It is then 
essential to consider stigma and discrimination as main barriers to health and access to 
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healthcare. But it is also vital to take social ecological perspectives to public health. This will 
allow us to address social-structural determinants of health, to improve health, protect the 
human and health rights of WOST, and reduce social and health inequities.   
Trust is key to delivering of pharmacy services (31-32), particularly among vulnerable and 
marginalized populations such as WOST. Our findings suggested that building a trusting 
relationship would enhance access to sexual health services among WOST. Building positive 
rapport would encourage women to express their concerns and overcome reluctance to discuss 
their sexual health. It may also have a significant role in promoting effective communication, 
and reducing perceived and enacted stigma. It is also essential that human and health rights are 
protected by treating WOST humanely, and reducing stigma and discrimination (33-36).  
Other barriers to providing sexual health services alongside OST were the pragmatic 
considerations of lack of privacy and time. The lack of time may have a negative impact on 
effective communication and limit the proactive promotion and provision of sexual health 
services. This could restrict the access to healthcare and thus be another factor that maintains 
health inequities for WOST. We therefore need to be careful that appropriate time and spaces 
are provided for delivering sexual health services. This may have implications on the funding 
needed for sexual health services, to ensure that community pharmacies have the necessary 
resources to implement these services. This links with another of the challenges identified: the 
need for funding. Commissioning sexual health services would be essential for implementing 
the services as community pharmacies cannot fund these services themselves.  
Limitations 
One of the main limitations is that this research did not include other women using drugs, and 
only included women who were already accessing health services. It is possible that 
incorporating the views of women who are not accessing services could have provided a broader 
insight on how to develop health services. Another limitation was that participants may had 
underreported some of their negative experiences and views. For instance, it may be that CPs 
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could have portrayed themselves more positively in their interactions with WOST. Likewise, 
CPs who decided to take part in the study were probably those who already held more positive 
views, experiences and relationships with WOST. Despite these limitations we also believe this 
study had several strengths, such as the comprehensive exploration of participants’ experiences 
by using qualitative research methodologies.   
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Key points 
• There are important opportunities to expand available public health services in 
community pharmacy to promote sexual health among WOST. 
• There are opportunities to improve how pharmacy services are being delivered. 
• Barriers need to be considered when developing and implementing public health 
services in community pharmacy. 
• Policies need to be improved to protect the health of WOST and other drug-using 
populations.  
• Improving access to healthcare services and protecting human and health rights of 
WOST should be at the core of public health services 
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Tables 
Table 1 
Characteristics of women on opioid substitution treatment taking part in the interviews 
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Participant characteristics (N=20) n (%) 
Age M=39.50 (SD=9.65) 
Ethnicity 
English/Welsh/Scottish/Northern Irish/British 
White European 
Black African 
 
18 (90) 
1 (5) 
1 (5) 
Primary language 
English 
 
20 (100) 
Education 
No academic qualifications 
0 Level/Scottish Higher or equivalent (NVQ/SVQ Level 2) 
A Level/Scottish Higher or equivalent (NVQ/SVQ Level 3) 
First degree 
 
8 (40) 
7 (35) 
3 (15) 
2 (10) 
Homelessness 
Current 
Lifetime 
 
3 (15) 
3 (15) 
Employment status 
Unemployed 
 
16 (80) 
Annual income (N=19) 
£ 0-4,999 
£ 5,000-9,999 
£ 10,000-14,999 
 
9 (45) 
7 (35) 
3 (15) 
Current drug use  
Tobacco 
Heroin 
Alcohol 
Methadone (prescribed and non-prescribed) 
 
20 (100) 
18 (90) 
17 (85) 
17 (85) 
18 
 
Crack cocaine 
Cannabis 
Benzodiacepines 
Codeine 
15 (75) 
15 (75) 
15 (75) 
13 (65) 
Opioid substitution treatment 
Methadone 
Buprenorphine 
Suboxone 
 
17 (70) 
5 (25) 
1 (5) 
Sexual partners 
Men only 
Women and men 
Women only 
 
14 (70) 
5 (25) 
1 (5) 
Transactional sex (lifetime) 8 (40) 
Sexual abuse (N=19) 17 (89.5) 
Sexual health  
STI/BBV preventive methods 
No sex 
None 
Male condom use 
STI/BBV screening (at least once) (N=18) 
STI/BBV diagnoses 
Hepatitis C  
Chlamydia  
Genital warts 
Pubic lice 
Scabies 
Gonorrhoea 
 
 
11 (55) 
5 (25) 
4 (20) 
17 (94.4) 
 
7 (35) 
4 (20) 
2 (10) 
2 (10) 
2 (10) 
1 (5) 
19 
 
Human Papillomavirus 1 (5) 
 
 
 
 
 
 
 
 
 
 
 
0 
 
Table 2 
.Community pharmacists’ characteristics. 
Semi-structured interviews Focus group 
 Sample Characteristics (N=14)  n (%) Sample Characteristics (N=3) n (%) 
Age M=36 
(SD=9.46) 
Age M=35.67 
(SD=13.32
) 
Sex 
Female 
Male 
 
7 (50) 
7 (50) 
Sex 
Female 
Male 
 
2 (66.7) 
1 (33.3) 
Ethnicity 
English/Welsh/Scottish/N
orthern Irish/British 
White European 
White non-European 
Indian 
Chinese 
Other  
 
5 (35.7) 
4 (28.6) 
1 (7.1) 
1 (7.1) 
2 (14.3) 
1 (7.1) 
Ethnicity 
English/Welsh/Scottish/N
orthern Irish/British 
Indian 
 
2 (66.7) 
1 (33.3) 
Primary language 
English 
Non-English 
 
7 (50) 
7 (50) 
Primary language 
English 
 
3 (100) 
Education 
First degree 
Postgraduate certificate of 
 
7 (50) 
1 (7.1) 
Education 
First degree 
 
3 (100) 
1 
 
education (PGCE) 
Other postgraduate 
qualification (including 
professional) 
Doctorate  
5 (35.7) 
1 (7.1) 
Employment status 
Work ≥ 16 hours /week 
Work < 16 hours/week 
Self-employed 
 
9 (64.3) 
1 (7.1) 
4 (28.6) 
Employment status 
Work ≥ 16 hours /week 
 
3 (100) 
Job title 
Superintendent 
pharmacist 
Pharmacy manager 
Responsible pharmacist 
Pharmacist 
Independent prescribing 
pharmacist 
 
2 (14.3) 
6 (42.9) 
3 (21.4) 
1 (7.1) 
2 (14.3) 
Job title 
Superintendent 
pharmacist 
Pharmacy manager 
Other 
 
1 (33.3) 
1 (33.3) 
1 (33.3) 
Time being a pharmacist (in 
months) 
M=145.64 
(SD=124.6
9) 
(12.14 
years) 
Time being a pharmacist (in 
months) 
M=144.67 
(SD=166.2
1) 
(12.05 
years) 
Responsible for OST 14 (100) Responsible for OST 3 (100) 
Time being a pharmacist 
responsible for opioid 
M=71.69 
(SD=69.68
Time being a pharmacist 
responsible for opioid 
M=24 
(SD=16.97
2 
 
substitution treatment (in 
months) (n=13) 
) 
(5.97 
years) 
substitution treatment (in 
months) (n=2) 
) 
(2 years) 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Participants’ verbatims 
The role of community pharmacists and 
key components for pharmacy services to 
promote sexual health 
 
“I think it would be more helpful cause it’s 
somewhere that they would be going to go 
and pick up their prescriptions and so it 
[sexual health service] would be there.” 
(Emmeline, 35 years old; WOST).  
“If it was a sort of health assessment that 
3 
 
would be easier to do with your daily 
methadone pick-ups because you could, have 
multiple attempts to sell them the idea.” 
(Matthew, 51 years old; CP; focus group).   
Potential challenges to overcome  
Intersectional stigma and discrimination: 
beyond drug use  
 
 
 
“It sort of it’s like everyone knows about 
methadone and I think that it… if I went with 
that I would think that I would be judged 
more.” (Marion, 37 years old; WOST).   
“[I was] just treated badly because you know, 
I was on methadone prescription, so… you 
know, it takes, it kind of makes you want not 
to engage with any of them.” (Lily, 36 years 
old; WOST).  
“I think one barrier that you probably won’t 
be able to overcome easily is the negative 
judgmental attitudes towards OST.” (Olivia, 
27 years old; CP; focus group).   
“When I came here [UK] it was a bit 
awkward. Because I couldn´t understand how 
the government can give to those people [OST 
clients] drugs [OST].” (Susan, 35 years old; 
CP; interview).   
 
Trust and humanity: building positive rapport 
and good communication  
 
“He’d [CP] sometimes ask if there are any 
problems, especially when I went through that 
stuff [intimate partner violence] when he [ex-
4 
 
partner] beat me up and that, cause he [CP] 
was seeing me every day so he [CP] was 
obviously seeing things (…).” (Sylvia, 27 
years old; WOST).   
“I’m firm with them and I threaten them and I 
say […] I will ring up and cancel the script 
and you can go elsewhere and that” (Martha, 
57 years old; CP; interview)  
 
Lack of privacy and time constraints: 
providing a space and time to share    
 
“It’s kind of quite embarrassing, you know, 
because you don’t really want people to know 
that you’ve been a drug addict you know”. 
(Lily, 36 years old; WOST).   
“(…) but you haven’t really got the time to sit 
in the consulting room with them and then you 
face a pile of prescriptions to come back to, 
that is unfortunately how it is” (Martha, 57 
years old; CP; interview).   
 
Financial limitations: community pharmacy as 
a business   
 
“Even though we want to help them, we can’t 
offer them anything free unless we are 
commissioned by the commissioning body” 
(Peter, 25 years old; CP; interview).   
 
